The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | BRUIN trial: LOXO-305 for B-cell malignancies
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses early results of the Phase I/II BRUIN trial (NCT03740529) evaluating a next-generation, highly selective Bruton’s tyrosine kinase (BTK) inhibitor LOXO-305 in heavily treated patients with previously treated B-cell malignancies. The study included a large cohort of patients with various histological subtypes of B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldernström’s macroglobulinemia (WM), diffuse large B-cell lymphoma (DLBL), and marginal zone lymphoma (MZL). The analysis showed good overall response rates (ORR) across a range of B-cell malignancies. Additionally, LOXO-305 showed a good safety profile with minimal serious adverse events across cohorts. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
